Trials / Completed
CompletedNCT03198585
Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction
Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction: A Randomized Clinical Trial (Empire HF)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 190 (actual)
- Sponsor
- Morten Schou · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
To assess the effect of Empagliflozin on cardiac biomarkers, cardiac function at rest and during stress, cardiac hemodynamics, renal function, metabolism, daily activity level and health-related quality of life in stable, symptomatic heart failure patients with reduced left ventricular ejection fraction. The primary hypothesis is that 3 months' treatment with Empagliflozin 10 mg a day will reduce the plasma concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Empagliflozin 10 MG | Capsule, once a day for 90 days |
| OTHER | Placebo | Capsule, once a day for 90 days |
Timeline
- Start date
- 2017-06-29
- Primary completion
- 2019-12-20
- Completion
- 2020-01-17
- First posted
- 2017-06-26
- Last updated
- 2020-02-05
Locations
2 sites across 1 country: Denmark
Source: ClinicalTrials.gov record NCT03198585. Inclusion in this directory is not an endorsement.